The ROE as of November 2024 (TTM) for Cullinan Oncology, Inc. (CGEM) is -26.54%

According to Cullinan Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -26.54%. This represents a change of 295.54% compared to the average of -6.71% of the last 4 quarters.

Cullinan Oncology, Inc. (CGEM) Historical ROE (quarterly & annually)

How has CGEM ROE performed in the past?

The mean historical ROE of Cullinan Oncology, Inc. over the last ten years is 25.83%. The current -26.54% ROE has changed -202.74% with respect to the historical average. Over the past ten years (40 quarters), CGEM's ROE was at its highest in in the December 2020 quarter at 36.51%. The ROE was at its lowest in in the March 2019 quarter at -14.29%.

Cullinan Oncology, Inc. (CGEM) ROE by Quarter and Year

Discovering the peaks and valleys of Cullinan Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cullinan Oncology, Inc. (CGEM) Average ROE

How has CGEM ROE performed in the past?

The current ROE of Cullinan Oncology, Inc. (CGEM) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cullinan Oncology, Inc. (CGEM) ROE vs. Peers

How is CGEM’s ROE compared to its peers?

Cullinan Oncology, Inc.’s ROE is greater than Bolt Biotherapeutics, Inc. (-69.46%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Autolus Therapeutics plc (-63.65%), greater than Sana Biotechnology, Inc. (-94.47%), greater than Olema Pharmaceuticals, Inc. (-53.55%), greater than aTyr Pharma, Inc. (-56.83%), greater than Zentalis Pharmaceuticals, Inc. (-43.92%), greater than Century Therapeutics, Inc. (-66.58%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Talaris Therapeutics, Inc. (-14.93%), greater than Adicet Bio, Inc. (-53.85%), greater than Vor Biopharma Inc. (-101.14%), greater than Lyell Immunopharma, Inc. (-34.64%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Revolution Medicines, Inc. (-33.67%),

Build a custom stock screener for Cullinan Oncology, Inc. (CGEM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cullinan Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cullinan Oncology, Inc. (CGEM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cullinan Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.